{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T20:25:09Z","timestamp":1781555109833,"version":"3.54.5"},"reference-count":63,"publisher":"Informa UK Limited","issue":"3","funder":[{"name":"grants funding from the Medical University of Lodz"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2022,3,4]]},"DOI":"10.1080\/17474086.2022.2054800","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T07:52:19Z","timestamp":1647503539000},"page":"183-194","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia"],"prefix":"10.1080","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8838-2098","authenticated-orcid":false,"given":"Anna","family":"Wolska-Washer","sequence":"first","affiliation":[{"name":"Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland"},{"name":"Department of Hematooncology, Copernicus Memorial Hospital, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-6357","authenticated-orcid":false,"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, Lodz, Poland"},{"name":"Department of General Hematology, Copernicus Memorial Hospital, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,3,29]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.019"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0567-7"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.06.069"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30019-4"},{"key":"cit0008","unstructured":"Fletcher CD, Gaballa S, Ghobadi A, et al. NCCN guidelines version 1.2022 chronic lymphocytic leukemia\/small lymphocytic lymphoma continue NCCN guidelines panel disclosures. 2021 [cited 2021 Dec 7]; Available from: https:\/\/www.nccn.org\/home\/member-"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.3109\/08830185.2013.786711"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.242909"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061396"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1042\/bst0320113"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.343"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0779-z"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1807934"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S288550"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108816"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018013060"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147641"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.6b00480"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030771"},{"issue":"5","key":"cit0023","first-page":"1224","volume":"8","author":"Uckun FM","year":"2002","journal-title":"Clin Cancer Res"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.14.9587"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200600221"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"cit0028","unstructured":"Imbruvica (ibrutinib) FDA approval history - drugs.com [Internet]. [cited 2021 Dec 7]. Available from: https:\/\/www.drugs.com\/history\/imbruvica.html."},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022369"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051103"},{"issue":"164","key":"cit0031","first-page":"722","volume":"2021","author":"McDonald C","journal-title":"Immunology"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13020"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00535-x"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3118.3118"},{"key":"cit0035","unstructured":"AstraZeneca. Update on CALAVI Phase II trials for Calquence in patients hospitalised with respiratory symptoms of COVID-19 [Internet]. [cited 2021 Nov 28]. Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2020\/update-on-calavi-phase-ii-trials-for-calquence-in-patients-hospitalised-with-respiratory-symptoms-of-covid-19.html."},{"key":"cit0036","unstructured":"Calquence (acalabrutinib) FDA approval history - drugs.com [Internet]. [cited 2021 Nov 13]. Available from: https:\/\/www.drugs.com\/history\/calquence.html."},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1130"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018884940"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128404"},{"key":"cit0041","author":"Sharman JP","journal-title":"Leukemia"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03355"},{"key":"cit0043","unstructured":"Acalabrutinib safety study in untreated and relapsed or refractory chronic lymphocytic leukemia patients - full text view - clinicaltrials.gov [Internet]. [cited 2021 Nov 26]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04008706?term=04008706&draw=2&rank=1."},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.272500"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1002\/hon.51_2880"},{"key":"cit0047","unstructured":"Study of acalabrutinib (ACP-196) in combination with venetoclax (ABT-199), with and without obinutuzumab (GA101) versus chemoimmunotherapy for previously untreated CLL - Full Text View - ClinicalTrials.gov. [cited 2021 Nov 26]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03836261?term=NCT03836261&draw=2&rank=1."},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00455-1"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123824"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30029-8"},{"key":"cit0051","unstructured":"Sequential regimen of bendamustin-debulking followed by obinutuzumab, acalabrutinib and venetoclax in patients with relapsed\/refractory CLL - Full Text View - ClinicalTrials.gov [Internet]. [cited 2021 Nov 27]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03787264."},{"key":"cit0052","unstructured":"cfDNA-based MRD assessment is feasible, yields highly concordant results in relapsed\/refractory CLL [Internet]. [cited 2021 Nov 27]. Available from: https:\/\/www.onclive.com\/view\/cfdna-based-mrd-assessment-is-feasible-yields-highly-concordant-results-in-relapsed-refractory-cll."},{"key":"cit0053","unstructured":"Acalabrutinib and venetoclax with or without early obinutuzumab for the treatment of high risk, recurrent, or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma - full text view - clinicaltrials.gov [Internet]. [cited 2021 Nov 27]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04169737."},{"key":"cit0054","unstructured":"Acalabrutinib and obinutuzumab for the treatment of chronic lymphocytic leukemia - full text view - clinicaltrials.gov [Internet]. [cited 2021 Nov 27]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04505254."},{"key":"cit0055","volume-title":"First interim analysis of alpine study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"330170","author":"Hillmen P","year":"2021"},{"key":"cit0056","unstructured":"Acalabrutinib study with best supportive care versus best supportive care in subjects hospitalized with COVID-19. full text view - clinicaltrials.gov [Internet]. [cited 2021 Nov 28]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04380688?term=acalabrutinib&cond=sars-cov-2&draw=2&rank=2."},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006288"},{"issue":"1","key":"cit0058","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1186\/s13063-020-04584-9","volume":"21","author":"Wilkinson T","year":"2020","journal-title":"Trials"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd0110"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01030-2"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01270-w"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011568"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00528-x"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2022.2054800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T11:05:02Z","timestamp":1650279902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2022.2054800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,4]]}},"alternative-id":["10.1080\/17474086.2022.2054800"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2022.2054800","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}